High-dose chemotherapy with rescue of autologous PBSC (auto-PBSCT) is regarded as the standard of care for newly diagnosed multiple myeloma (MM) in patients under 65 years of age. 1, 2 Recently, new drugs such as thalidomide or bortezomib have been introduced for myeloma treatment and the overall survival of MM patients has been improving. 3 However, the prognosis of patients with refractory or relapsed MM is still poor. Allogeneic SCT (allo-SCT) is the only potentially curative treatment for MM but it is associated with high treatment-related mortality (TRM). A total of 30-50% of patients who survive the first year remain disease-free at 3-6 years. Such durable remissions have been attributed to a graft-versusmyeloma (GVM) effect. Non-myeloablative or dose-reduced allograft (mini-allograft) has recently been explored as a safer alternative to conventional high-dose transplant regimens. 4 Auto-PBSCT followed by mini-allograft was superior to tandem autologous transplantation in terms of survival. 5 Molecular monitoring of minimal residual disease (MRD) is important for evaluating patients after allo-SCT, 6 but there is no report on MRD monitoring after the tandem auto-allo approach. Herein, we report the results on high-risk myeloma patients who underwent tandem auto-mini-allograft. Subsequent MRD detection was carried out using allele-specific oligonucleotide (ASO) primers.
Patients with MM under 65 years old, who failed to achieve CR with conventional chemotherapy or relapsed, and who had an HLA-identical sibling donor, were eligible. Between April 2000 and April 2006 10 patients were enrolled, but PBSC could not be harvested from two patients and they received only mini-allografts; therefore, 8 patients (age: median, 49.5 years; range, 36-53 years) were analyzed ( Table 1) .
PBSC were collected from the patient after administration of CY 4 g m À2 followed by G-CSF. If the amount of harvested stem cells was less than 2.0 Â 10 6 kg
À1
, stem cell mobilization was performed by G-CSF alone. The conditioning regimen for auto-PBSCT consisted of melphalan 100 mg m À2 on days À3 and À2. Mini-allograft was performed between 50 and 90 days after auto-PBSCT. The conditioning regimen for allografting consisted of fludarabine 25 mg m À2 for 5 days plus melphalan 70 mg m À2 for 2 days or 100 mg m À2 for 1 day. GVHD prophylaxis consisted of MTX with CY or FK506. PBSC were mobilized from the donor with G-CSF (400 mg m À2 per day). Hematological and molecular responses after transplantation. MRD was detected by subjecting BM samples to nested PCR using ASO primers that had been designed at CDR2 and CDR3. J ¼ molecular remission; ¼ hematological CR without molecular remission; ¼ PR or residual disease; A ¼ alive;
The patients underwent auto-PBSCT with a median infused CD34 þ cell number of 3.3 Â 10 6 cells kg À1 (range, 1.8-5.3). There were no severe complications associated with auto-PBSCT and they underwent allo-grafting 67 days (median; range, 52-90) post-auto-PBSCT. The first six patients received 140 mg m À2 melphalan, while the last two patients received 100 mg m À2 melphalan. The median transplanted CD34 þ cell number for allografting was 5.3 Â 10 6 kg À1 (range, 4.5-7.5). No primary or secondary graft failure was observed. At 28 days post-allo transplant, 100% donor chimera was observed in PB T cells of all eight patients. Six patients developed acute GVHD (grade 2: five patients, grade 1: one patient). Patients with grade 2 acute GVHD were treated with 1-2 mg kg À1 prednisolone (PSL), and all showed a good response. Six patients developed chronic GVHD, three cases of which were the extensive type.
Hematological CR was achieved in six patients and PR in two patients after allograft. To detect MRD after transplant, the following procedure was performed using each patient's BM samples. Genomic DNA from a pretransplantation BM sample was amplified by PCR using a panel of VH family-specific primers together with JH consensus primers of the immunoglobulin heavy chain (IgH) gene. 6 As for patient 8 with Bence Jones protein (BJP) l protein, Vl regions were amplified. 7 The obtained PCR products were confirmed to be monoclonal by heteroduplex analysis and were directly sequenced. 8 After sequencing, ASO primers were designed at the CDR2 and CDR3 regions. BM samples were subjected to nested PCR using these ASO primers for detection of MRD. After auto-PBSCT, MRD was detected in all patients. After mini-allograft, five patients (patients 1, 3, 6, 7 and 8) achieved molecular remission and four of these patients are currently alive without MRD (patients 1, 6, 7 and 8) (Figure 1) . In patient 1, 10% of the myeloma cells remained in the BM on day 28 post-allograft. He developed grade 2 acute GVHD in the skin on day 30 and was treated with 2 mg kg À1 PSL. Then, the number of BM myeloma cells rapidly decreased and he achieved molecular remission 6 months post-transplant. Although patient 2 achieved only hematological PR post-allograft, he is currently alive 6 years 9 months post-autograft. Three patients (patients 3, 4 and 5) died and the primary causes of death were aspergillosis, disease progression and interstitial pneumonia.
These results demonstrate that reduced-intensity conditioning followed by allografting after prior cytoreductive autograft is sufficient to establish durable and stable engraftment and to induce molecular remission in highrisk myeloma patients. Five of the eight refractory or relapsed myeloma patients achieved molecular remission after receiving a mini-allograft. Of note, four patients achieved molecular remission within 2 months after allograft, indicating that eradication of myeloma cells by the GVM effect occurs in the early phase after allograft. One patient had residual myeloma cells in his BM on day 28 post-allograft, but after developing acute GVHD he achieved hematological CR. Moreover, he achieved molecular remission after developing chronic GVHD. These results indicate that a GVM effect can induce molecular remission even in patients who have obvious residual myeloma cells after transplantation.
Table 1
Characteristics of the patients and results of auto-PBSCT followed by dose-reduced allograft Kro¨ger et al. 9 investigated the feasibility of tandem autoallo transplantation with reduced-intensity conditioning after a 3-month interval. After autografting with 200 mg m À2 melphalan, 17 patients received a regimen consisting of fludarabine, melphalan and antithymocyte globulin followed by allografting from related or unrelated donors. The TRM and CR rates at a median of 13 months after allografting were 11 and 73%, respectively. Our regimen of fludarabine 125 mg m À2 with melphalan at 140 or 100 mg m À2 had sufficient intensity for successful engraftment. The initial autologous transplantation may have induced significant host immunosuppression, which then led to rapid and sustained full donor engraftment after allografting.
Although the number of patients in this study was limited, we conclude that tandem auto-allo transplantation provides rapid and sustained engraftment with durable, complete donor chimerism with tolerable toxicity and can lead to molecular remission in patients with refractory or relapsed MM.
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